DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR IDAMYCIN
Clinical Trials for Idamycin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002812 | Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia | Completed | National Cancer Institute (NCI) | Phase 3 | 1996-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia. |
| NCT00002812 | Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia | Completed | Children's Oncology Group | Phase 3 | 1996-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia. |
| NCT00002816 | Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia | Completed | National Cancer Institute (NCI) | Phase 3 | 1996-12-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia. |
| NCT00002816 | Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia | Completed | Children's Oncology Group | Phase 3 | 1996-12-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia. |
| NCT00002833 | Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia | Completed | National Cancer Institute (NCI) | Phase 2 | 1994-10-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Idamycin
Condition Name
Condition MeSH
Clinical Trial Locations for Idamycin
Trials by Country
Clinical Trial Progress for Idamycin
Clinical Trial Phase
Clinical Trial Sponsors for Idamycin
Sponsor Name
